An Essential Role for Argonaute 2 in EGFR-KRAS Signaling in Pancreatic Cancer Development
By
Sunita Shankar,
Jean Ching-Yi Tien,
Ronald F Siebenaler,
Seema Chugh,
Vijaya L Dommeti,
Sylvia Zelenka-Wang,
Jessica Waninger,
Kristin M Juckette,
Alice Xu,
Xiao-Ming Wang,
Malay Mody,
Sanjana Eyunni,
Andrew Goodrum,
Grace Tsaloff,
Yuping Zhang,
Ingrid J Apel,
Lisha Wang,
Javed Siddiqui,
Richard D Smith,
Heather A Carlson,
John J.G. Tesmer,
Xuhong Cao,
Jiaqi Shi,
Chandan Kumar-Sinha,
Howard C. Crawford,
Arul M. Chinnaiyan
Posted 30 Nov 2017
bioRxiv DOI: 10.1101/227264
(published DOI: 10.1038/s41467-020-16309-2)
KRAS and EGFR are known essential mediators of pancreatic cancer development. In addition, KRAS and EGFR have both been shown to interact with and perturb the function of Argonaute 2 (AGO2), a key regulator of RNA-mediated gene silencing. Here, we employed a genetically engineered mouse model of pancreatic cancer to define the effects of conditional loss of AGO2 in KRAS G12D -driven pancreatic cancer. Genetic ablation of AGO2 does not interfere with development of the normal pancreas or KRAS G12D -driven early precursor pancreatic intraepithelial neoplasia (PanIN) lesions. Remarkably, however, AGO2 is required for progression from early to late PanIN lesions, development of pancreatic ductal adenocarcinoma (PDAC), and metastasis. AGO2 ablation permits PanIN initiation driven by the EGFR-RAS axis, but rather than progressing to PDAC, these lesions undergo profound oncogene-induced senescence (OIS). Loss of Trp53 (p53) in this model obviates the requirement of AGO2 for PDAC development. In mouse and human pancreatic tissues, increased expression of AGO2 and elevated co-localization with RAS at the plasma membrane is associated with PDAC progression. Furthermore, phosphorylation of AGO2Y393 by EGFR disrupts the interaction of wild-type RAS with AGO2 at the membrane, but does not affect the interaction of mutant KRAS with AGO2. ARS-1620, a G12C-specific inhibitor, disrupts the KRASG12C-AGO2 interaction specifically in pancreatic cancer cells harboring this mutant, demonstrating that the oncogenic KRAS-AGO2 interaction can be pharmacologically targeted. Taken together, our study supports a biphasic model of pancreatic cancer development: an AGO2 -independent early phase of PanIN formation reliant on EGFR-RAS signaling, and an AGO2 -dependent phase wherein the mutant KRAS-AGO2 interaction is critical to prevent OIS in PanINs and allow progression to PDAC.
Download data
- Downloaded 1,069 times
- Download rankings, all-time:
- Site-wide: 21,614
- In cancer biology: 518
- Year to date:
- Site-wide: 72,470
- Since beginning of last month:
- Site-wide: 92,113
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!